



REVOLUTIONIZE YOUR DRUG DISCOVERY

[WWW.HELIGENICS.COM](http://WWW.HELIGENICS.COM)

# About Us

- **Heligenics' proven breakthroughs in biotechnology power our GigaAssay™ to deliver high-quality biologic leads – at accelerated 4x speed!**
- **Our GigaAssay generates a MEGA-MAP™ activity and variant landscape**
- **Outpace the competition – Heligenics supercharges biologics discovery that is scalable at a significantly lower cost**

# Tackling Multiple Sclerosis: A Massive Opportunity

- **Over 1 million Americans are battling Multiple Sclerosis (MS) – a relentless disease with limited treatment durability, rising costs, and no cure in sight**
- **Current clinical approaches and their limitations**
  - Once a standard of care IFN- $\beta$ , a treatment molecule, offers only **modest efficacy** and does not prevent long-term disability
  - Harmful side effects are driving patients and providers to **abandon outdated options**
  - Today's drugs deliver more efficacy – and **more problems**
- **Challenges in new IFN- $\beta$  drug development**
  - **High costs and long timelines** limit pre-clinical development
  - **Slow, tedious methods** are choking innovation and stalling lead discovery

# IFN- $\beta$ Solution

## Biobetter for Multiple Sclerosis

**GigaAssay: proprietary technology that drives market-shifting cost savings.**

- 4X faster
- 90%+ success in validation of lead<sup>1</sup> generation

Market Opportunity	Heligenics Solutions
<b>Increase potency</b>	Rapidly pinpoint potent IFN- $\beta$ variants from 100k+ leads to reduce dosing and side effects
<b>Improved stability</b>	Discover stable leads that reduce dosing – no guesswork
<b>Reduced immunogenicity</b>	Engineered for immune stealth – maximize efficacy over time
<b>Oral forms</b>	Unlock oral delivery with innovative molecular tweaks and natural modifications
<b>Customized biologics</b>	MEGA-Map landscapes reveal full variant activity 4x faster than conventional single-track technology

<sup>1</sup>prioritized drug candidates

# Our GigaAssay Technology for Discovery of Next-Generation IFN- $\beta$ Drug Leads

Our patented GigaAssay leverages Heligenics' technology to rapidly screen >100k IFN- $\beta$  variants for precise, highly impactful results

- **Breakthrough efficiency: lower costs, faster launch**
- **Discovery and lead verification 4x faster than conventional methods**
  - Less than one year with GigaAssay vs US average of 4.5 years
  - Rapid asset validation: *A single GigaAssay will deliver up to 50 actionable leads in <1 year*
- **Tailored assays drive 90%+ projected clinical trial success**
- **GigaAssay accelerates lead validation with vast libraries and MEGA-Map landscapes**

# How? – With the GigaAssay


## 100k's of leads tested in human cells - *simultaneously*

>100k different IFN- $\beta$  leads simultaneously

Cell-based GigaAssay measures bioactivity

Visualize GigaAssay data output for bioactivity

Purify, verify, patent leads for clinical testing





# THANK YOU

---

**Dr. Martin Schiller**  
**[mschiller@heligenics.com](mailto:mschiller@heligenics.com)**

**Heligenics Inc.**  
**10530 Discovery Drive**  
**Las Vegas, NV 89135**  
**[www.heligenics.com](http://www.heligenics.com)**

